Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Kyowa Kirin
Kyowa Kirin
With mid-stage AML win, Kura details dual-track Phase III program for ziftomenib
First Word Pharma
Wed, 02/5/25 - 10:52 pm
Kura Oncology
Kyowa Kirin
ziftomenib
AML
Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns
Fierce Pharma
Tue, 02/4/25 - 06:37 pm
Bristol Myers Squibb
layoffs
New Jersey
Kyowa Kirin
Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA
Fierce Biotech
Thu, 11/21/24 - 11:14 am
Kyowa Kirin
Kura Oncology
ziftomenib
AML
With new focus, Kyowa Kirin pulls decades-old breast cancer drug Fareston from US market
Fierce Pharma
Mon, 08/26/24 - 11:13 am
Kyowa Kirin
Fareston
breast cnacer
After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US
Fierce Pharma
Mon, 03/18/24 - 05:16 pm
Orchard Therapeutics
Kyowa Kirin
M&A
Lenmeldy
FDA
metachromatic leukodystrophy
Kyowa Kirin plans $200M plant in NC, where it'll hire 100-plus new employees
Fierce Pharma
Fri, 03/1/24 - 11:42 am
Kyowa Kirin
North Carolina
hirings
drug manufacturing
Kyowa Kirin enrols first subject in Phase II diabetic macular edema trial
Clinical Trials Arena
Wed, 02/7/24 - 11:23 am
Kyowa Kirin
clinical trials
tivozanib
diabetic macular edema
How Kyowa Kirin is Giving Employees a Voice in the Company's Future
BioSpace
Mon, 12/11/23 - 10:11 am
Kyowa Kirin
employees
Kyowa Kirin to acquire Orchard Therapeutics for $478 million
Reuters
Thu, 10/5/23 - 11:43 am
Kyowa Kirin
Orchard Therapeutics
M&A
Kyowa Kirin Opens New Jersey Headquarters
BioSpace
Thu, 07/20/23 - 09:40 pm
Kyowa Kirin
New Jersey
headquarters
After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop
Fierce Biotech
Fri, 11/18/22 - 10:45 am
Kyowa Kirin
MEI Pharma
zandelisib
clinical trials
non-Hodgkin lymphoma
If at first... pharma’s most drawn-out development timelines revealed
EP Vantage
Thu, 11/3/22 - 10:54 am
Kyowa Kirin
Takeda
Eiger BioPharmaceuticals
AstraZeneca
Teva Pharmaceutical
Bavarian Nordic
Halozyme
Novartis
MannKind
drug development
Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Endpoints
Thu, 08/4/22 - 11:03 am
Amgen
Kyowa Kirin
clinical trials
AMG 451
atopic dermatitis
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Pharmaforum
Mon, 07/18/22 - 09:53 am
Kyowa Kirin
KW-6356
clinical trials
Parkinson's Disease
Kyowa Kirin Could Sell $1B in Assets as it Advances PI3K Inhibitor
BioSpace
Thu, 06/16/22 - 10:44 pm
Kyowa Kirin
Ardelyx amends license deal with Kyowa Kirin for tenapanor
Pharmaceutical Business Review
Tue, 04/12/22 - 10:40 am
Ardelyx
Kyowa Kirin
tenapanor
FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin
BioSpace
Fri, 03/25/22 - 10:35 am
MEI Pharma
Kyowa Kirin
FDA
zandelisib
PI3k inhibitor
Amgen reveals midphase eczema data behind its $400M bet
Fierce Biotech
Mon, 10/4/21 - 10:38 am
Amgen
Kyowa Kirin
clinical trials
eczema
antibodies
Amgen follows Sanofi into a new dermatitis mechanism
EP Vantage
Tue, 06/1/21 - 10:58 am
Amgen
Sanofi
atopic dermatitis
Ichnos
KHK4083
Kyowa Kirin
Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy
Fierce Pharma
Fri, 01/29/21 - 10:00 am
Ultragenyx
FDA
Crysvita
tumor-induced osteomalacia
Kyowa Kirin
Dojolvi
Pages
1
2
next ›
last »